News archive
GLP‑1 news from 2004
2 dated, sourced GLP-1 developments from 2004: approvals, trial results, prices, lawsuits, compounding and culture.
- Research
XENDOS publishes: orlistat cuts diabetes progression over four years
The four-year XENical in the prevention of Diabetes in Obese Subjects trial (n=3,305) reports mean weight loss of 5.8 kg with orlistat versus 3.0 kg with placebo at four years, and a fall in progression to type 2 diabetes from 9.0% to 6.2% (HR 0.63). It remains the longest randomized trial of an approved weight drug.
- Competition
FDA bans dietary supplements containing ephedrine alkaloids
The only time the FDA has removed an entire supplement ingredient from the US market. Bitter orange (p-synephrine) becomes the primary replacement stimulant in weight-loss and sports supplements, and subsequent research finds reformulated 'ephedra-free' products have similar acute cardiovascular stimulant actions.